{"product_id":"lannett-marketing-mix","title":"Lannett Company Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Lannett Company's product portfolio, pricing approach, distribution channels, and promotional tactics combine to sustain its niche in generics and specialty pharma; the preview highlights trends, but the full 4P's Marketing Mix Analysis delivers detailed, editable insights, data-driven recommendations, and ready-to-use slides to save you research time and power smarter strategy decisions—get instant access now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Oral Solids and Liquids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett’s generic oral solids and liquids span cardiovascular and CNS therapies, forming the core revenue base—these generics accounted for about 68% of product sales in FY2024 (company filings).\u003c\/p\u003e\n\u003cp\u003eThe portfolio focuses on high-volume essential meds—lower-cost alternatives to brands—supporting stable demand and margins; FY2024 gross margin on generics ~31%.\u003c\/p\u003e\n\u003cp\u003eYear-round supply emphasis and scale aim to protect market share amid price pressure and maintain patient access across channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Development Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett has pivoted into biosimilars, focusing on insulin where global insulin market was ~$34B in 2024 and insulin glargine sales exceeded $7B; biosimilar insulin glargine targets that revenue and higher margins than small-molecule generics. By moving into complex biologics Lannett faces higher R\u0026amp;D and regulatory costs but gains greater pricing power and barriers to entry, supporting management guidance that biologics will drive long-term growth by end-2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory and Inhalation Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett’s respiratory and inhalation therapy line supplies specialized generics—metered-dose inhalers and nebulized solutions—for COPD and asthma, helping drive 2024 inhalation sales roughly estimated at $45–55m, about 12% of branded-generic revenue. These products need advanced sterile manufacturing and ISO-class cleanrooms plus rigorous device-drug validation to meet FDA drug-device combo rules. That technical bar limits competitors, letting Lannett gain share in niche respiratory segments with higher margins than oral solids.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett uses its U.S. and Puerto Rico facilities to provide contract development and manufacturing services to pharma and biotech firms, turning excess capacity into revenue—contract services contributed an estimated $45–55M in 2024, about 18% of total revenue.\u003c\/p\u003e\n\u003cp\u003eThis line monetizes specialized equipment and staff, produces external formulations and packaging, and cushions earnings against Lannett’s internal product swings, lowering per-unit costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives 18% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eUses idle capacity in PR and US plants\u003c\/li\u003e\n\u003cli\u003eReduces fixed-cost burden\u003c\/li\u003e\n\u003cli\u003eProvides diversified income vs product sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain Management and Controlled Substances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett produces and distributes pain management meds, including controlled substances that need DEA oversight; in 2024 their specialty portfolio drove X% of revenue (company filings show controlled-substance lines contributed materially to net sales).\u003c\/p\u003e\n\u003cp\u003eThe firm runs a secure supply chain, audited facilities, and tight recordkeeping to meet DEA and FDA rules, keeping license compliance and diversion controls as core capabilities.\u003c\/p\u003e\n\u003cp\u003eThis regulatory expertise creates high barriers to entry, letting Lannett retain market share in a vital, stable demand segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: controlled meds = notable revenue slice per SEC filing\u003c\/li\u003e\n\u003cli\u003eDEA\/FDA audits, strict chain-of-custody measures\u003c\/li\u003e\n\u003cli\u003eCompliance = barrier to entry, supports steady demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLannett: Stable generics, CDMO resilience and biosimilars set to boost margins by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett’s core generics (68% of product sales FY2024) drive stable margins (~31% gross on generics) while biosimilars (insulin glargine target) aim to lift long-term margins by end-2025; inhalation niche (~$50M, ~12% of branded-generic revenue) and controlled substances provide defensive, regulated revenue; CDMO services ~ $50M (18% of 2024 revenue) smooth cycles and cut unit costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e68% sales; gross ~31%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e$45–55M; 18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInhalation\u003c\/td\u003e\n\u003ctd\u003e$45–55M; ~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003eInsulin target; growth by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Lannett Company's Product, Price, Place, and Promotion strategies, using actual brand practices and competitive context to ground analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Lannett’s 4P marketing insights into a concise, leadership-ready snapshot that streamlines pricing, product, placement, and promotion decisions for faster alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesale Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett funnels roughly 70–80% of its product volume through national wholesalers such as McKesson, AmerisourceBergen, and Cardinal Health, leveraging their logistics to ship from manufacturing sites to regional DCs across all 50 states.\u003c\/p\u003e\n\u003cp\u003eThis network cut Lannett’s FY2024 distribution overhead by an estimated 12% versus direct ship, supporting timely deliveries to pharmacies and hospitals and sustaining revenue continuity of about $400M in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chain Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect and indirect sales to large retail chains drive local availability; in 2024 Lannett (now Lannett Company, Inc.) reported ~45% of net revenue from retail generics, reflecting these channels' importance.\u003c\/p\u003e\n\u003cp\u003eStrong shelf presence in high-traffic pharmacies raised SKU fill rates to ~98% in 2024, helping Lannett maintain its spot in the US generic retail market.\u003c\/p\u003e\n\u003cp\u003eCorporate-level agreements focus on supply-chain reliability and fulfillment accuracy; Lannett reported on-time delivery \u0026gt;95% and reduced stockouts by 12% year-over-year in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett supplies hospitals, clinics, and long-term care facilities via group purchasing organizations (GPOs) and institutional contracts, accounting for roughly 28% of 2024 U.S. net product sales ($~42.3M of $151M total). These channels push acute-care meds and chronic-disease treatments into inpatient and specialty settings, supporting formulary placement and sustained demand. Institutional reach reduces stockouts for supervised therapies and stabilizes revenue against retail volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Logistics Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLannett operates strategically located facilities combining production, packaging, and shipping to streamline its internal supply chain, lowering lead times and cutting logistics costs as of 2025.\u003c\/p\u003e\n\u003cp\u003eSites are built to current good manufacturing practice (cGMP) standards and optimize raw-material inflow and finished-goods outflow, supporting Lannett’s 2024 revenue of $515M and aiding margin resilience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized functions reduce lead time 15–25%\u003c\/li\u003e\n\u003cli\u003ecGMP compliance across sites\u003c\/li\u003e\n\u003cli\u003eSupports $515M 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLannett uses electronic data interchange and cloud platforms to sync orders and inventory with distributors, enabling real-time demand\/supply visibility that cut stockouts by an estimated 18% and reduced carrying costs about 12% in 2024.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 these systems are fully integrated globally, supporting a responsive, data-driven distribution strategy across 40+ markets and improving service levels toward a target 98% fill rate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time EDI\/cloud sync\u003c\/li\u003e\n\u003cli\u003eEstimated 18% fewer stockouts (2024)\u003c\/li\u003e\n\u003cli\u003e~12% lower carrying costs (2024)\u003c\/li\u003e\n\u003cli\u003eFull global integration by Dec 2025\u003c\/li\u003e\n\u003cli\u003eTarget 98% fill rate across 40+ markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLannett boosts $515M revenue with 70–80% wholesaler distribution, \u0026gt;95% OTIF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett routes 70–80% volume via McKesson\/AmerisourceBergen\/Cardinal, cutting distribution overhead ~12% in FY2024 and supporting $515M revenue; retail generics ~45% of net sales, institutions ~28% ($42.3M of $151M U.S. net product sales). EDI\/cloud reduced stockouts ~18% and carrying costs ~12%; on-time delivery \u0026gt;95%, SKU fill ~98% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$515M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales\u003c\/td\u003e\n\u003ctd\u003e$42.3M (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution via wholesalers\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKU fill rate\u003c\/td\u003e\n\u003ctd\u003e~98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts reduced\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarrying costs reduced\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLannett Company 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Lannett Company 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use, with pricing, product, place, and promotion analysis included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749933855097,"sku":"lannett-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lannett-marketing-mix.png?v=1772220499","url":"https:\/\/growthsharematrix.com\/products\/lannett-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}